Company Number: 13815295

Analysis Date: 2025-07-29 16:14 UTC

Financial Health Assessment Report for PARVISHPHARMA LTD

---

1. Financial Health Score: Grade D

Explanation:
PARVISHPHARMA LTD is classified as a dormant company with minimal financial activity and virtually no operational financial data beyond the initial share capital. The company maintains a nominal net asset and shareholders’ funds balance of £1 consistently over four years. This indicates no active trading or business transactions—essentially a "financial patient" in a state of dormancy rather than growth or decline. While there are no immediate signs of distress, the absence of operational financial activity limits the ability to assess underlying business health or future prospects.

---

2. Key Vital Signs

Metric	Value	Interpretation
Company Status	Active	Company is legally active but dormant in trading terms
Account Category	Dormant	No significant financial transactions during the year
Net Assets (2024)	£1	Minimal asset base; no operational capital
Shareholders’ Funds (2024)	£1	Solely initial share capital; no retained earnings
Financial History	2021-2024	No change in net assets or equity; no trading activity
Director	1 (Parvish Singh Tank)	Controls 75-100% of shares and voting rights
Industry SIC Code	46460	Wholesale of pharmaceutical goods (inactive currently)
Filing Compliance	Up to date	Accounts and returns filed timely, no overdue filings

Interpretation:

• The company’s financial "vital signs" indicate a healthy compliance status but zero operational or trading activity, akin to a patient in remission or resting state without active symptoms.
• The sole director and primary shareholder retains full control, with no complexity in ownership or governance.

---

3. Diagnosis

Dormant Status with No Trading Activity:
The company is not currently conducting business operations, as evidenced by dormant accounts and unchanged net assets of £1 over multiple years. This is typical for companies that have been incorporated but have not yet commenced trading or have been intentionally kept inactive. The absence of revenue, expenses, or liabilities means there are no financial symptoms indicating distress such as cash flow problems, increasing debt, or declining equity.

Governance and Compliance:
The company maintains good "administrative health" by filing accounts and confirmation statements on time, avoiding penalties or regulatory concerns. The director’s conduct record appears clean, and control is straightforward, which minimizes governance risk.

Underlying Business Health:
From a clinical perspective, the company is in a state of financial dormancy with no active metabolic processes (business transactions). While this avoids risks associated with active trade (losses, debts), it also means no growth, income, or asset accumulation is occurring. The business is essentially in stasis.

---

4. Prognosis

Short-Term Outlook:
If the company remains dormant, it will continue to show minimal financial movement and maintain a stable but inert financial position. This is sustainable as long as compliance is maintained.

Long-Term Outlook:
To transition to a "healthy active" financial state, PARVISHPHARMA LTD would need to initiate trading activities, incur operating revenues and expenses, and build assets or equity. Without such activity, the company risks becoming obsolete or potentially being struck off for inactivity if compliance lapses.

---

5. Recommendations

• Activate Trading or Operational Plans:
  To improve financial vitality, the company should consider commencing its wholesale pharmaceutical activities or other planned operations. This will introduce cash flow, revenues, and opportunities for profit accumulation.

• Maintain Compliance Vigilance:
  Continue timely filing of dormant accounts and confirmation statements to avoid penalties and ensure good standing.

• Consider Strategic Review:
  Evaluate the purpose of maintaining the dormant company. If not intended for future trade, consider formal dissolution to avoid ongoing administrative burden.

• Prepare for Financial Monitoring:
  Once trading begins, implement regular financial monitoring to detect early symptoms of distress such as cash flow shortages or rising liabilities.

---

Executive Summary